ArcticZymes Signs Enzyme Supply Agreement with New England Biolabs

Tromsø, Norway, 2 November 2012 – ArcticZymes AS, the Tromsø-based manufacturer of innovative heat-labile molecular biology enzymes, has signed a supply agreement with New England Biolabs Inc. (NEB) for the supply of Recombinant Shrimp Alkaline Phosphatase (SAP) from ArcticZymes.  NEB plans to offer SAP through its global distribution network. The agreement also allows for the introduction of other ArcticZymes’ products through NEB at a later date.

“We are delighted to expand the reach for our SAP product through this agreement with New England Biolabs, one of the global leaders in the life science market. We believe our enzymes will add value to NEB’s already outstanding product portfolio, and look forward to having the NEB global distribution network greatly increase the addressable market for our products,” states Dr. Jan Buch Andersen, Managing Director at ArcticZymes.

“We are constantly seeking to add unique, quality products that further strengthen our expanding portfolio,” states Dr. Peter Nathan, Executive Director of Global Business Development at NEB. “We expect Recombinant Shrimp Alkaline Phosphatase (SAP) to be a nice addition.”

ArcticZymes AS is a subsidiary of Biotec Pharmacon ASA.

No financial or other deal terms have been disclosed.

For further information, please contact

Jan Buch Andersen, Managing Director ArcticZymes AS, tel: +47 4674 6171

Svein Lien, CEO Biotec Pharmacon ASA, tel: +47 9228 9323

About ArcticZymes® AS:

ArcticZymes® AS develops, produces and sells enzymes used in the molecular biology research and - diagnostic markets. The market is dynamic and growing, and the rapid and diversifying technological development creates a strong market demand for new and improved enzymes. More information on

About Biotec Pharmacon:

Biotec Pharmacon is a biopharmaceutical company that develops and manufactures new immunomodulatory products and cold adapted marine enzymes. The wholly owned Biotec BetaGlucans AS focuses on identifying, developing and commercializing innovative products within wound treatment, cancer and gastroenterology. The company’s technology is protected by a large patent portfolio covering, amongst others, the use of yeast beta-glucans as adjuvants in conjunction with monoclonal antibodies. The subsidiary ArcticZymes® AS aspires to become a leading supplier of novel enzymes for diagnostics and genetic research. More information on

About New England Biolabs, Inc.:

Established in the mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, cellular analysis, epigenetics and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and subsidiaries located in Canada, China, France, Germany, Japan and the UK. For more information about New England Biolabs visit